The first of two pivotal phase 3 trials that will assess the safety and efficacy of Brimochol PF for the treatment of presbyopia is underway, according to a press release from Visus Therapeutics.
Healio/Ocular Surgery News Presbyopia Section Editor George O. Waring IV, MD, FACS, said the initiation of the trial is an important step in the expanding market of presbyopia treatments.
“With more than 128 million presbyopes in the United States and over 2 billion worldwide, the market and interest for presbyopia treatments is at an all-time high,” Waring told Healio/OSN. “We are